The D1 receptor antagonist, SCH 23390, induces signs of parkinsonism in African green monkeys.
Systemic administration of the selective D1 antagonist, SCH 23390, caused significant motor changes in healthy African green monkeys. The effects included the parkinsonian signs of motor freezing, incoordination, bradykinesia, poverty of movement, tremor and depressed blink rate. SCH 23390 administered to MPTP-treated monkeys increased existing parkinsonism. The results are of particular interest in light of recent data that demonstrate the effectiveness of dihydrexidine, a full D1 agonist, in alleviating parkinsonism in MPTP-treated monkeys. These data implicate D1 receptors in the functions impaired by Parkinson's disease and suggest the possibility of parkinsonian side effects in the clinical use of this or similar D1 antagonists as treatments for psychiatric disorders.
Lawrence
M S
MS
Neurobehavior Laboratory, Yale University School of Medicine, New Haven, Ct. 06510.
Redmond
D E
DE
Elsworth
J D
JD
Taylor
J R
JR
Roth
R H
RH
D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001552:Benzazepines / Q000494:pharmacology*; D001767:Blinking / Q000187:drug effects; D002522:Chlorocebus aethiops; D018492:Dopamine Antagonists; D008297:Male; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000502:physiology; D017447:Receptors, Dopamine D1
D001552:Benzazepines; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1